Latest Conference Articles

October 5th 2017, 10:26pm

Global Congress on Bladder Cancer

As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.

September 18th 2017, 3:00pm

International Liver Cancer Association Annual Conference

Direct acting antivirals are a novel and completely oral hepatitis C therapy that is associated with a high response rate in hepatocellular carcinoma (HCC).

September 17th 2017, 11:56pm

International Liver Cancer Association Annual Conference

BLU-554 induced an overall response rate of 16% in patients with FGF19-positive hepatocellular carcinoma.

September 17th 2017, 11:51pm

Lynn Sage Breast Cancer Symposium

Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses endocrine therapy for patients with breast cancer.

September 17th 2017, 11:49pm

Lynn Sage Breast Cancer Symposium

Arti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, City of Hope, discusses challenges facing geriatric patients with breast cancer.

September 17th 2017, 11:46pm

Lynn Sage Breast Cancer Symposium

Ongoing studies are hoping to find a biomarker to guide which premenopausal women with ER-positive breast cancer need extended adjuvant therapy and which need ovarian function suppression.

September 17th 2017, 10:56pm

Lynn Sage Breast Cancer Symposium

Treating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.

September 17th 2017, 10:33pm

Lynn Sage Breast Cancer Symposium

The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.

September 17th 2017, 10:22pm

International Liver Cancer Association Annual Conference

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the purpose of the CheckMate-040 trial, which explored nivolumab (Opdivo) in patients with hepatocellular carcinoma. (HCC).

September 17th 2017, 10:21pm

International Liver Cancer Association Annual Conference

Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses biomarker findings of the phase III STORM trial, which explored adjuvant treatment with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

September 17th 2017, 10:18pm

International Liver Cancer Association Annual Conference

First-line therapy with lenvatinib continued to be noninferior in overall survival and achieve significant improvements in progression-free survival, time to progression, and objective response rate compared with sorafenib for patients with unresectable hepatocellular carcinoma.

September 16th 2017, 11:13pm

Lynn Sage Breast Cancer Symposium

Health investment is failing to match the challenge presented by a growing cancer burden in countries at all economic levels, enhancing the need for new approaches that help optimize the delivery of care.

September 16th 2017, 10:15pm

Lynn Sage Breast Cancer Symposium

There is a significant transformation underway in the treatment of breast cancer as research advances and new laboratory techniques continue to shrink the so-called "undruggable genome."

September 16th 2017, 9:23pm

Lynn Sage Breast Cancer Symposium

Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses adjuvant therapy for elderly patients with HER2-positive or triple-negative breast cancer (TNBC).

September 16th 2017, 9:02pm

International Liver Cancer Association Annual Conference

Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival for patients with hepatocellular carcinoma treated with adjuvant sorafenib; however, a predictive biomarker for recurrence was not uncovered.

September 16th 2017, 8:44pm

International Liver Cancer Association Annual Conference

Precision screening for hepatocellular carcinoma (HCC) could improve on current screening techniques through its risk-stratifying approach.

September 16th 2017, 8:17pm

Lynn Sage Breast Cancer Symposium

Patients have a hard time with artificially induced menopause and some research suggests it may have a negligible effect on the success of their treatment.

September 16th 2017, 8:07pm

Lynn Sage Breast Cancer Symposium

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses treatment for premenopausal patients with breast cancer.

September 16th 2017, 3:59pm

International Liver Cancer Association Annual Conference

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

September 16th 2017, 1:58pm

International Liver Cancer Association Annual Conference

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agents will eventually fit into the paradigm of hepatocellular carcinoma. (HCC).